Christina Annunziata, MD, PhD of National Institutes of Health discusses how some novel agents may meet the guidelines for accelerated approval in phase 2-3 design trials. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.
Some Drugs May Meet Guidelines for Accelerated Approval in Phase 2-3 Design Trials
